Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01288326
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.

Study Details

The study is conducted in Europe. The aim of this observational study is to assess glycaemic control while using liraglutide under normal clinical practice conditions in Belgium.

Key Dates

Start date
Feb 28, 2011
Status verified
Jan 2017
Primary completion
Mar 31, 2013
Completion
Mar 31, 2013

Study Design

Enrollment
254 participants (actual)

Arms

  • Arm: A

Primary Outcome Measure

Percentage of participants with a decrease in HbA1c (glycosylated haemoglobin A1c) of at least 1% [ Time Frame: month 12 ]

Related Studies